Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Alimentary Pharmacology & Therapeutics
|
October 24, 2014
Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis
J S Bajaj, A C Barrett, E Bortey, et al.
Journal of the National Medical Association
|
October 1, 1991
The effectiveness of labetalol compared to hydrochlorothiazide in hypertensive black patients
C Lucas, P Jenkins, J Mendels, et al.
Alimentary Pharmacology & Therapeutics
|
November 7, 2007
Clinical trial: sodium phosphate tablets are preferred and better tolerated by patients compared to polyethylene glycol solution plus bisacodyl tablets for bowel preparation
G R Lichtenstein, N Grandhi, M Schmalz, et al.
Journal of Vascular Surgery
|
March 24, 1998
Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease
S R Money, J A Herd, J L Isaacsohn, et al.
Vascular Medicine (London, England)
|
January 16, 2002
Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication
E R Mohler, H G Beebe, S Salles-Cuhna, et al.
Alimentary Pharmacology & Therapeutics
|
April 5, 2014
Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials
P Schoenfeld, M Pimentel, L Chang, et al.
Archives of Internal Medicine
|
October 8, 1999
A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial
H G Beebe, D L Dawson, B S Cutler, et al.
Alimentary Pharmacology & Therapeutics
|
May 24, 2012
Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials
G R Lichtenstein, S Zakko, G L Gordon, et al.
Alimentary Pharmacology & Therapeutics
|
October 13, 2010
Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial
G R Lichtenstein, G L Gordon, S Zakko, et al.
The American Journal of Medicine
|
November 7, 2000
A comparison of cilostazol and pentoxifylline for treating intermittent claudication
D L Dawson, B S Cutler, W R Hiatt, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Alimentary Pharmacology & Therapeutics
|
October 24, 2014
Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis
J S Bajaj, A C Barrett, E Bortey, et al.
Journal of the National Medical Association
|
October 1, 1991
The effectiveness of labetalol compared to hydrochlorothiazide in hypertensive black patients
C Lucas, P Jenkins, J Mendels, et al.
Alimentary Pharmacology & Therapeutics
|
November 7, 2007
Clinical trial: sodium phosphate tablets are preferred and better tolerated by patients compared to polyethylene glycol solution plus bisacodyl tablets for bowel preparation
G R Lichtenstein, N Grandhi, M Schmalz, et al.
Journal of Vascular Surgery
|
March 24, 1998
Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease
S R Money, J A Herd, J L Isaacsohn, et al.
Vascular Medicine (London, England)
|
January 16, 2002
Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication
E R Mohler, H G Beebe, S Salles-Cuhna, et al.
Alimentary Pharmacology & Therapeutics
|
April 5, 2014
Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials
P Schoenfeld, M Pimentel, L Chang, et al.
Archives of Internal Medicine
|
October 8, 1999
A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial
H G Beebe, D L Dawson, B S Cutler, et al.
Alimentary Pharmacology & Therapeutics
|
May 24, 2012
Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials
G R Lichtenstein, S Zakko, G L Gordon, et al.
Alimentary Pharmacology & Therapeutics
|
October 13, 2010
Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial
G R Lichtenstein, G L Gordon, S Zakko, et al.
The American Journal of Medicine
|
November 7, 2000
A comparison of cilostazol and pentoxifylline for treating intermittent claudication
D L Dawson, B S Cutler, W R Hiatt, et al.
Page
of 3